

October 01, 2019

To, The Manager Listing Department, **The National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051

Dear Sir/Madam,

**Trading Symbol: ZOTA** 

Sub: Product Registration in Turkmenistan

Ref.: Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that we, Zota Health Care Limited (the "Company") have received product registration licenses for below mentioned two products from Turkmenistan.

Sr. No.	Name of Product	Therapeutic Category
1	ZOTAMET 500 (Tablet – Each tablet contains Metformin 500mg)	Antidiabetic
2	ZOTAMET 850 (Tablet – Each tablet contains Metformin 850mg)	Antidiabetic

We have received licenses for the aforementioned products for the validity period of five years, license for the products are also renewable. Company shall start exporting these products in Turkmenistan very soon.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited

Ashvin Variya (Company Secretary & Compliance Officer) Place: Surat



## **Registered Office :**

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com Web : www.zotahealthcare.com

## Plant :

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122